Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D1XW
|
|||
| Former ID |
DIB010936
|
|||
| Drug Name |
PEG-Interferon lambda (IL-29)
|
|||
| Indication | Virus infection [ICD-11: 1A24-1D9Z] | Phase 1 | [1] | |
| Company |
ZymoGenetics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-29 (IL29) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| WikiPathways | Type III interferon signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00565539) Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection. U.S. National Institutes of Health. | |||
| REF 2 | Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.